GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Short Percentage of Float

VRCDF (Verici Dx) Short Percentage of Float


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Verici Dx's Short Percentage of Float

For the Diagnostics & Research subindustry, Verici Dx's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's Short Percentage of Float Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Verici Dx's Short Percentage of Float falls into.


;
;

Verici Dx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Short Percentage of Float
Comparable Companies
LSE:GENI LSE:OBD LSE:GDR LSE:PRM LSE:ABDX TSE:2397 TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA LH WAT DGX XPAR:BIM ILMN
Traded in Other Exchanges
VRCI:UK 63V:Germany
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Website
https://www.vericidx.com
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines